Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199245 | 0.79 | ALOX5AP (0.43) | ALOX5APFEN1NMUR2DGAT1GAA | |
| SCHEMBL31129057 | 0.77 | ALOX5AP (0.35) | ALOX5APFEN1KMT2ANMUR2DGAT1 | |
| SCHEMBL3824986 | 0.72 | MAPT (0.42) | MEN1KMT2AKMOGAA | |
| SCHEMBL27871315 | 0.70 | RAB9A (0.44) | MEN1KMT2AGAAHTT | |
| SCHEMBL14520998 | 0.70 | DGAT1 (0.46) | ALOX5APFEN1NMUR2DGAT1BCL2 | |
| SCHEMBL31310573 | 0.70 | DGAT1 (0.46) | ALOX5APFEN1NMUR2DGAT1BCL2 | |
| SCHEMBL27164738 | 0.69 | BCL2 (0.45) | ALOX5APFEN1MEN1KMT2ANMUR2 | |
| SCHEMBL12302791 | 0.68 | ALOX5AP (0.50) | ALOX5APFEN1 | |
| SCHEMBL30957357 | 0.68 | ESR1 (0.44) | MEN1KMT2A | |
| SCHEMBL28107900 | 0.68 | MAPT (0.41) | MEN1KMT2AKMOGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3404032-A2 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303043-B2 | Process for making benzoxazepin compounds | GREENTECH, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2970329-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | PIK3C2B, PIP4K2C, PIK3C2A | ALOX5AP 2002/4885FEN1 3940/4885MEN1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.